BC biomarkers, including the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67, are well-established prognostic factors that play crucial roles in determining biological subtypes and guiding therapeutic strategies for patients [3,4]. This evidence concerns the gene MKI67 and breast cancer.